background
respiratori
tract
infect
among
common
infect
winter
season
rapid
diagnost
requir
clinic
decis
make
regard
isol
patient
appropri
therapi
object
aim
studi
evalu
analyt
clinic
perform
characterist
panther
respiratori
panel
use
publish
laboratorydevelop
realtim
pcr
assay
ldt
studi
design
analyt
sensit
panther
flu
abrsv
assess
test
dilut
cell
cultur
isol
clinic
perform
assess
includ
complet
panther
respiratori
panel
fluabrsv
piv
advhmpvrv
consist
retrospect
prospect
studyarm
retrospect
evalu
includ
store
sampl
collect
februari
januari
prospect
evalu
perform
unselect
pretreat
respiratori
tract
sampl
patient
present
hospit
novemb
may
result
analyt
sensit
gener
slightli
lower
panther
assay
clinic
specif
sensit
respect
discrep
result
found
sampl
sampl
test
ldt
posit
panther
neg
sampl
ldt
neg
panther
posit
total
ten
discrep
sampl
ctvalu
sequenc
confirm
presenc
rvc
notdetect
ldt
rva
detect
panther
conclus
panther
provid
randomaccess
system
continu
load
much
shorter
sampletoansw
time
compar
ldt
albeit
slightli
less
clinic
sensit
compar
ldt
winter
season
viral
respiratori
tract
infect
among
common
infect
sever
children
elderli
immunocompromis
patient
often
lead
hospit
fast
reliabl
laboratori
test
essenti
patient
manag
mani
laboratori
develop
multiplex
qrtpcr
assay
detect
respiratori
virus
recent
also
commerci
pcr
assay
becom
avail
assay
use
pointofcar
poct
consist
limit
panel
eg
influenza
b
virus
comprehens
panel
detect
larg
number
virus
even
atyp
respiratori
bacteria
contrast
poct
respiratori
viru
pcr
assay
fast
easi
perform
laboratori
develop
test
ldt
requir
highli
qualifi
personnel
perform
interpret
result
much
longer
time
result
h
handson
time
among
other
separ
nucleic
acid
extract
amplif
analysi
qc
evalu
panther
accessori
respiratori
viru
panel
panther
autom
random
access
system
molecular
detect
continu
load
turnaround
time
h
throughput
respiratori
tract
sampl
within
h
analyt
sensit
repeat
perform
use
dilut
seri
cell
cultur
isol
influenza
viru
influenza
b
viru
flubyamagatanetherland
respiratori
syncyti
viru
rsv
rsvb
dilut
seri
prepar
aliquot
store
use
test
replic
panther
flu
abrsv
assay
routin
laboratori
develop
autom
realtim
rtpcr
ldt
use
aurora
flow
roch
almer
netherland
describ
rel
analyt
sensit
determin
probit
analysi
posit
use
ibm
spss
competit
interfer
flu
abrsv
assay
assess
use
pair
target
virus
differ
concentr
rang
serial
dilut
run
determin
sensit
target
presenc
high
amount
influenza
ab
rsv
ab
repeat
assay
assess
use
five
replic
posit
process
control
contain
correspond
viru
determin
stabil
sampl
panther
specimen
lysi
tube
stm
one
replic
process
control
test
day
week
clinic
perform
evalu
retrospect
prospect
retrospect
evalu
store
pretreat
respiratori
tract
sampl
collect
februari
januari
select
includ
known
ldtposit
sampl
flua
flub
rsv
sampl
parainfluenza
virus
piv
human
metapneumoviru
hmpv
human
rhinoviru
rv
well
adenoviru
adv
sampl
known
posit
multipl
target
sampl
test
complet
panther
respiratori
panel
panther
fluabrsv
paraflu
advhmpvrv
retest
ldt
confirm
origin
result
prospect
evalu
perform
unselect
pretreat
respiratori
tract
sampl
patient
present
hospit
novemb
may
suspicion
infect
respiratori
viru
pretreat
sputa
sp
broncho
alveolar
lavag
bal
nasal
wash
nw
perform
describ
briefli
pretreat
consist
dilut
step
dulbecco
modifi
eagl
medium
dmem
lonza
biowittak
vervier
belgium
includ
lonza
biowittak
vervier
belgium
acid
hepe
lonza
biowhittak
penicillin
streptomycin
greiner
bioon
alphen
ad
rijn
netherland
amphotericin
b
bristolmey
squibb
woerden
netherland
foetal
bovin
serum
lonza
biowhittak
min
centrifug
rpm
hettich
rotina
beun
de
rond
abcoud
netherland
supernat
store
directli
use
nucleic
acid
test
pretreat
sampl
ad
panther
specimen
lysi
tube
contain
specimen
transport
media
stm
day
routin
ldt
assay
perform
stm
store
maximum
h
panther
assay
perform
describ
manufactur
sampl
discrep
result
ct
valu
repeat
panther
ldt
confirm
discrep
analyz
sanger
sequenc
rv
bp
fragment
adv
fragment
hexon
gene
amplifi
sequenc
use
termin
cycl
sequenc
kit
thermo
fisher
scientif
genet
analyz
appli
biosystem
sequenc
analyz
use
seqman
pro
lasergen
softwar
dna
star
genotyp
determin
use
ncbi
blastn
databas
statist
analysi
perform
use
ibm
spss
confid
interv
sampl
proport
calcul
use
wilson
method
epitool
http
epitoolsausvetcomau
competit
interfer
within
fluabrsv
assay
singl
target
flu
h
ct
rel
analyt
sensit
determin
probit
analys
hitrat
differ
rel
sensit
panther
ldt
flua
flub
rsva
rsvb
respect
presenc
two
virus
variou
concentr
test
establish
multiplex
capac
assay
high
amount
influenza
viru
result
undetect
intern
control
slightli
less
analyt
sensit
rsva
b
virus
tabl
contrast
high
amount
influenza
b
viru
rsva
b
effect
sensit
repeat
determin
calcul
coeffici
variat
cv
five
replic
posit
process
control
replic
target
test
posit
mean
ctvalu
cv
measur
week
within
ctvalu
differ
compar
initi
result
virus
except
ctvalu
differ
total
respiratori
tract
sampl
sampl
type
distribut
tabl
clinic
sensit
specif
determin
use
retrospect
prospect
sampl
ldt
gold
standard
tabl
result
specif
virus
except
rv
sensit
panther
vari
fig
discrep
sampl
neg
panther
type
discrep
sampl
ct
consid
discrep
due
small
differ
sensit
assay
investig
sequenc
studi
evalu
perform
panther
flu
abrsv
paraflu
advhmpvrv
assay
compar
wellvalid
ldt
assay
rel
analyt
sensit
panther
system
slightli
less
flu
ab
rsv
compar
ldt
correspond
slightli
less
clinic
sensit
adv
sensit
compar
ldt
addit
panther
sam
et
al
found
presum
fals
posit
result
hmpv
sampl
studi
also
found
hmpvposit
sampl
panther
ct
neg
ldt
amplif
curv
reevalu
exhibit
lowfluoresc
could
result
ambigu
interpret
uncommon
multiplex
syndrom
pcr
panel
less
sensit
compar
wellestablish
ldt
assay
syndrom
panel
often
depend
uniform
nucleic
acid
isol
pcr
procedur
tradeoff
sensit
consolid
linear
regress
show
good
correl
ldt
panther
virus
except
rv
find
could
explain
larg
sequenc
divers
rv
addit
rv
ldt
assay
design
detect
rhinoviru
type
c
strain
effici
also
contribut
lower
correl
number
posit
sampl
assay
low
n
appear
divid
two
differ
subgroup
whether
attribut
genet
differ
strain
potenti
primerprob
mismatch
could
investig
primer
probe
sequenc
unknown
sinc
commerci
compani
tend
share
data
although
adv
good
correl
assay
demonstr
panther
miss
high
posit
sampl
retrospect
studi
like
due
mismatch
primerprob
sampl
includ
studi
detect
properli
two
sampl
low
ct
valu
miss
panther
remain
unclear
panther
respiratori
assay
offici
ceivd
approv
nasopharyng
swab
howev
diagnost
set
common
respiratori
tract
sampl
throat
swab
sputa
bal
nasal
wash
therefor
materi
ad
studi
sputa
bal
nasal
wash
pretreat
accord
diagnost
standard
protocol
direct
use
materi
test
intern
control
within
assay
limit
accord
panther
softwar
howev
softwar
declar
result
invalid
intern
control
neg
viru
test
posit
consequ
certain
degre
pcr
inhibit
toler
panther
specif
case
laboratori
could
formul
addit
cutoff
valu
intern
control
would
monitor
interpret
user
addit
case
instanc
high
posit
influenza
viru
result
intern
control
may
neg
presum
competit
result
reject
panther
softwar
theoret
coinfect
instanc
influenza
b
viru
rsv
low
amount
viru
could
inadvert
report
neg
tabl
due
pcr
inhibit
monitor
correctli
panther
respiratori
panel
includ
coronavirus
enteroviru
bocaviru
syndrom
respiratori
panel
eplex
genmark
xtag
rvp
luminex
panel
distinguish
rhinoor
enterovirus
eplex
quicker
turnaround
time
min
wherea
turnaround
time
xtag
h
requir
handson
time
although
first
panther
result
produc
approxim
h
everi
min
five
addit
complet
panel
result
gener
panther
also
provid
open
channel
ldt
test
adapt
run
simultan
respiratori
panel
ceivd
assay
furthermor
one
extract
total
three
pcr
reaction
perform
allow
effici
use
sampl
limit
volum
conclus
although
slightli
less
sensit
compar
optim
ldt
assay
panther
accessori
respiratori
viru
panel
offer
reliabl
fulli
autom
system
minimum
handson
time
eas
use
short
sampletoansw
time
studi
approv
medic
ethic
commiss
erasmu
mc
studi
support
research
grant
holog
deutschland
gmbh
